Back to Journals » Breast Cancer: Targets and Therapy » Volume 10

Protein expression profile and microRNA expression signature in estrogen receptor-positive and -negative breast cancers: report of two cases

Authors Tsunoda Y, Sasaki A, Sakamoto N, Teraoka K, Nakagawa R, Koshida Y, Fukuma E

Received 27 July 2018

Accepted for publication 16 October 2018

Published 23 November 2018 Volume 2018:10 Pages 195—199

DOI https://doi.org/10.2147/BCTT.S181652

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Cristina Weinberg

Peer reviewer comments 3

Editor who approved publication: Professor Pranela Rameshwar


Yuko Tsunoda,1 Akiko Sasaki,2 Naomi Sakamoto,1 Kou Teraoka,1 Rie Nakagawa,1 Yoshitomo Koshida,1 Eisuke Fukuma1

1Department of Breast Surgery, Breast Center, Kameda Medical Center, Chiba, Japan; 2Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan

Background:
Identification of the proteins that are associated with estrogen receptor (ER) status is a first step in selecting drugs against hormone-dependent breast cancer. Recently, the proteins associated with ER status were reported using liquid chromatography and tandem mass spectrometry, and microRNA (miRNA) profiling of breast cancer subtype was demonstrated using real-time-PCR.
Methods: We present herein two cases with differential protein expression and miRNA profiling in ER-positive and -negative breast cancer.
Results: Proteins associated with fatty acid metabolism were uniquely detected in ER-positive breast cancer. The level of miR-181a expression in ER-positive cancer was higher than that in ER-negative cancer, while the expression of miR-27a, miR-107, and miR-195 was lower in ER-positive compared with ER-negative cancer.
Conclusion: These cases suggest that fatty acid synthase (FAS) and FAS-related miRNAs are important in ER-positive breast cancer.
Keywords: breast cancer, estrogen receptor, fatty acid synthase, microRNA
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]